Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease (NCT05698979) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Evaluation of Botulinum TOXin Type a in the Treatment of Buerger's Disease
8 participantsStarted 2025-01-01
Plain-language summary
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years
✓. patient with Buerger's disease according to Olin criteria (ref)
✓. with digital ischemia with critical upper or lower limb ischemia criteria defined as Upper limb: pain and/or trophic disorders for at least 15 days AND digital pressure less than 50 mmHg Or TCPO2 30 mmHg) Or/and Lower limb: pain and/or trophic disorders for at least 15 days AND ankle pressure less than 50 mmHg (70 mmHg if diabetes), or 30 mmHg at the toe (50 mmHg if diabetes) or TCPO2 30 mmHg).
✓. Ability to attend study visits
✓. Ability to complete daily study agenda
✓. Ability to give free and informed consent
✓. Membership of a Social Security scheme
Exclusion criteria
✕. History of myasthenia gravis or Eaton-Lambert syndrome
✕. History of inflammatory myositis for less than 2 years or pre-existing motor neuron disease or superior limb neuropathy.
✕. Known allergy to botulinum toxin or cream lidocaine, albumin or inhaled nitrous oxide/oxygen.
✕. Progressive infection of one hand or foot
✕. Aminoglycoside treatment
✕. Pregnant or nursing women
What they're measuring
1
Feasibility in Number of patients
Timeframe: through study completion, an average of 18 months